Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Flatt

Showing results (11-20 of 325) with videos related to

Pageof 33
Sort By:
Best Practice & Research. Clinical Endocrinology & Metabolism|December 7, 2007
Incretin hormone mimetics and analogues in diabetes therapeuticsBrian D Green, Peter R Flatt
Peptides|February 1, 2020
Editorial: GIP renaissancePeter R Flatt, J Michael Conlon
Expert Opinion on Investigational Drugs|August 12, 2010
Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?Nigel Irwin, Victor Gault, Peter R Flatt
Diabetes|April 18, 2015
A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed MiceNigel Irwin, Varun Pathak, Peter R Flatt
Diabetic Medicine : a Journal of the British Diabetic Association|September 25, 2021
Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapiesNeil Tanday, Peter R Flatt, Nigel Irwin
Clinical Medicine Insights. Endocrinology and Diabetes|March 15, 2024
Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes MellitusAsif Ali, Peter R Flatt, Nigel Irwin
British Journal of Pharmacology|April 6, 2021
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligandsNeil Tanday, Peter R Flatt, Nigel Irwin
Diabetes|May 22, 2016
Erratum. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice. Diabetes 2015;64:2996-3009Nigel Irwin, Varun Pathak, Peter R Flatt
Peptides|February 23, 2008
Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed miceNigel Irwin, Kerry Hunter, Peter R Flatt
Peptides|February 8, 2018
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetesVarun Pathak, Peter R Flatt, Nigel Irwin
Pageof 33

Showing results (11-20 of 325) with videos related to

Sort By:
Pageof 33
Best Practice & Research. Clinical Endocrinology & Metabolism|December 7, 2007
Incretin hormone mimetics and analogues in diabetes therapeuticsBrian D Green, Peter R Flatt
Peptides|February 1, 2020
Editorial: GIP renaissancePeter R Flatt, J Michael Conlon
Expert Opinion on Investigational Drugs|August 12, 2010
Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?Nigel Irwin, Victor Gault, Peter R Flatt
Diabetes|April 18, 2015
A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed MiceNigel Irwin, Varun Pathak, Peter R Flatt
Diabetic Medicine : a Journal of the British Diabetic Association|September 25, 2021
Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapiesNeil Tanday, Peter R Flatt, Nigel Irwin
Clinical Medicine Insights. Endocrinology and Diabetes|March 15, 2024
Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes MellitusAsif Ali, Peter R Flatt, Nigel Irwin
British Journal of Pharmacology|April 6, 2021
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligandsNeil Tanday, Peter R Flatt, Nigel Irwin
Diabetes|May 22, 2016
Erratum. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice. Diabetes 2015;64:2996-3009Nigel Irwin, Varun Pathak, Peter R Flatt
Peptides|February 23, 2008
Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed miceNigel Irwin, Kerry Hunter, Peter R Flatt
Peptides|February 8, 2018
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetesVarun Pathak, Peter R Flatt, Nigel Irwin
Pageof 33